PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention...

Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study...

GH Research Reports Third Quarter 2022 Financial Results and Provides Business...

Legally Psychedelic: The Regulatory Environment from Oregon to Colorado

Psychedelics Weekly – Psilocybin-Assisted Psychotherapy for I.B.S., NY Aims to Legalize,...

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101...

atai’s PCN-101 Candidate Fails to Meet Primary Endpoint in Heavily-Anticipated Phase...

Reunion Neuroscience Inc. Provides 2023 Corporate Update

FILAMENT HEALTH ANNOUNCES CEO YEAR END LETTER AND CHANGE TO BOARD...

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for...

Load more